May 11, 2017 / 3:32 AM / 3 months ago

BRIEF- Astellas Pharma to discontinue ASP8273 treatment and close randomization for clinical study protocol 8273-CL-0302

1 Min Read

May 11(Reuters) - Astellas Pharma Inc

* Says it announced the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib

* Says it is voluntarily closing study randomization

Source text in Japanese:goo.gl/YgQQTz

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below